Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy and Safety of Peginesatide in the Treatment of Anemia in Patients With Chronic Kidney Disease

This study has been completed.
Information provided by (Responsible Party):
Takeda Identifier:
First received: April 13, 2006
Last updated: November 29, 2016
Last verified: November 2016
The purpose of this study is to evaluate the ability of peginesatide to increase and maintain increased hemoglobin levels in participants with chronic kidney disease (CKD) (either not on dialysis, receiving regular hemodialysis or peritoneal dialysis, or following renal transplant) with confirmed antibody-mediated pure red cell aplasia (PRCA).

Condition Intervention Phase
Chronic Kidney Disease
Chronic Renal Failure
Pure Red Cell Aplasia
Drug: peginesatide
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Study to Investigate the Efficacy and Safety of Peginesatide in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients With Chronic Kidney Disease

Resource links provided by NLM:

Further study details as provided by Takeda:

Primary Outcome Measures:
  • Proportion of participants who increase and maintain hemoglobin levels (two consecutive values) greater than or equal to the lower limit of the target range in the absence of red blood cell transfusion in the previous 28 days by Week 24. [ Time Frame: 24 weeks ]

Secondary Outcome Measures:
  • Number of red blood cell transfusions during the 26 week pre-treatment period (prior to enrollment) and during 13- and 26 week intervals during the study. [ Time Frame: 26 weeks prior to enrollment to end of study ]
  • Time to initial achievement of hemoglobin greater than or equal to the lower limit of the target range in the absence of red blood cell transfusions in the previous 28 days. [ Time Frame: While On Study ]
  • Proportion of participants with red blood cell transfusions during the 26 week pre-treatment period (prior to enrollment) and during 13- and 26 week intervals during the study. [ Time Frame: 26 weeks prior to enrollment to end of study ]

Enrollment: 22
Study Start Date: April 2006
Study Completion Date: October 2016
Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Peginesatide
Peginesatide dose administered subcutaneously once every 4 weeks. The frequency of each injection and the dose may be adjusted based on the participant's hemoglobin response and the ability to maintain a hemoglobin level in the range of 10.0-12.0 g/dL.
Drug: peginesatide
Other Names:
  • Omontys
  • Hematide
  • AF37702 Injection

Detailed Description:

This is an open-label treatment study; all patients enrolled into the study will receive AF37702 Injection. Hematologic data prior to treatment with AF37702 Injection will be compared to values obtained during treatment with AF37702 Injection (see Section 6.2).

CKD patients with documented antibody-mediated PRCA, hemoglobin level < 10 g/dL (without ESA therapy) or require transfusions to maintain this hemoglobin level, and who meet the eligibility criteria will be enrolled. It is anticipated that up to 40 patients will be enrolled in the trial.

The first group of 5 patients will receive a starting dose of 0.05 mg/kg, administered every 4 weeks (for this study, 1 month is defined as 4 weeks). Based on the assessment of the dose response in this initial group of 5 patients, it is recommended the starting dose in subsequent patients be increased to 0.075 mg/kg. The individual dose of AF37702 Injection will be modified based on hemoglobin levels. Dose adjustments will be made in order to achieve and maintain hemoglobin in the target range of 10.0-12.0 g/dL (see Section 5.4.1). The frequency of dosing may be decreased and dosing ultimately discontinued if Hgb is maintained within the target range. Due to the lack of treatment options in this population, more frequent dosing is justified in cases of a suboptimal response. If the Investigator determines that a patient has a suboptimal response despite dose increases, the frequency of injections may be increased up to once every other week, but the total dose may not exceed 0.35 mg/kg every 4 weeks.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participants who have confirmed antibody-mediated PRCA are potentially eligible for enrollment into this study.
  • Participants must be ≥ 18 years old at the time of consent.
  • ESAs must be discontinued for a minimum of 1 month prior to screening.
  • Participant requires periodic transfusions to maintain hemoglobin.
  • Hemoglobin < 10 g/dL for at least 2 measurements or participant has received a transfusion within the past 4 weeks to achieve a hemoglobin > 10 g/dL.
  • Confirmation that an anti-erythropoietin antibody sample was obtained for analysis by the central reference laboratory within 1 month prior to baseline.
  • Participants can either be participants with chronic kidney disease not yet requiring renal replacement therapy (participants not on dialysis), those on regular hemodialysis or peritoneal dialysis, or following a renal transplant.
  • Participants may or may not have previously been treated with immunosuppressive therapy.
  • Pre-menopausal females (with the exception of those who are surgically sterile) must have a negative pregnancy test at screening.
  • Written informed consent must be obtained.

Exclusion Criteria:

  • Participants already successfully on another erythropoietic agent.
  • Abnormal bone marrow findings consistent with the diagnosis of myelodysplasia, a myeloproliferative disorder, hematologic malignancy or evidence of metastatic infiltration.
  • Poorly controlled hypertension.
  • Previous exposure to any investigational agent within 4 weeks prior to administration of study drug or planned receipt during the study period.
  • High likelihood of early withdrawal or interruption of the study.
  • Participants who refuse to give informed consent.
  • Women who are pregnant, lactating or not using a medically approved birth control.
  • Life expectancy < 12 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00314795

Research Facility
Paris, France
Research Facility
Erlangen, Germany
United Kingdom
Research Facility
Derby, United Kingdom
Research Facility
London, United Kingdom
Sponsors and Collaborators
Study Director: Medical Director Takeda
  More Information

Responsible Party: Takeda Identifier: NCT00314795     History of Changes
Other Study ID Numbers: AFX01-06
2005-004944-30 ( EudraCT Number )
Study First Received: April 13, 2006
Last Updated: November 29, 2016

Keywords provided by Takeda:
pure red cell aplasia
chronic kidney disease
chronic renal failure
erythropoiesis stimulating agent
red blood cell
red blood cell production

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Renal Insufficiency
Kidney Failure, Chronic
Red-Cell Aplasia, Pure
Hematologic Diseases
Urologic Diseases processed this record on May 24, 2017